

Ref. No: 0956
Date: 24/05/24
Subject: Multiple Sclerosis Treatments

REQUEST

1. How many patients has your Trust treated in the past six months (for any disease) with the following drugs:
 - a. Aubagio (teriflunomide)
 - b. Avonex (interferon beta-1a)
 - c. Betaferon (interferon beta-1b)
 - d. Brabio (glatiramer acetate)
 - e. Copaxone (glatiramer acetate)
 - f. Extavia (beta interferon-1b)
 - g. Gilenya (fingolimod)
 - h. Kesimpta (ofatumumab)
 - i. Lemtrada (alemtuzumab)
 - j. Mavenclad (cladribine)
 - k. Mayzent (siponimod)
 - l. Ocrevus (ocrelizumab)
 - m. Plegridy (peginterferon beta-1a)
 - n. Ponvory (ponesimod)
 - o. Rebif (beta interferon-1a)
 - p. Tecfidera (dimethyl fumarate)
 - q. Tysabri (natalizumab)
 - r. Tysabri (natalizumab) pre-filled syringes only
 - s. Vumerity (diroximel fumarate)
 - t. Zeposia (ozanimod)
2. How many patients has your Trust treated with Rituximab for MS (Multiple Sclerosis) in the past six months?
3. How many patients within your Trust have a diagnosis of MS (Multiple Sclerosis)?
4. Of the patients with a diagnosis of Multiple Sclerosis, how many patients have a diagnosis of:
 - a. RRMS – Relapse Remitting Multiple Sclerosis
 - b. PPMS – Primary Progressive Multiple Sclerosis
 - c. SPMS – Secondary Progressive Multiple Sclerosis

RESPONSE

St Helens and Knowsley Teaching Hospitals NHS Trust and Southport and Ormskirk Hospital NHS Trust became a single legal entity known as Mersey and West Lancashire Teaching Hospitals NHS Trust on 1st July 2023, as such parts of the response may be provided in two sections relating to the hospital sites of each of the legacy organisations.

1. How many patients has your Trust treated in the past six months (for any disease) with the following drugs:

Drug Name	No. Patients
Aubagio (teriflunomide)	0
Avonex (interferon beta-1a)	0
Betaferon (interferon beta-1b)	0
Brabio (glatiramer acetate)	0
Copaxone (glatiramer acetate)	0
Extavia (beta interferon-1b)	0
Gilenya (fingolimod)	0
Kesimpta (ofatumumab)	0
Lemtrada (alemtuzumab)	0
Mavenclad (cladribine)	0
Mayzent (siponimod)	0
Ocrevus (ocrelizumab)	0
Plegridy (peginterferon beta-1a)	0
Ponvory (ponesimod)	0
Rebif (beta interferon-1a)	0
Tecfidera (dimethyl fumarate)	0
Tysabri (natalizumab)	0
Tysabri (natalizumab) pre-filled syringes only	0
Vumerity (diroximel fumarate)	0
Zeposia (ozanimod)	<5

Section 40: personal information

We are unable to provide precise figures when those figures refer to individuals in volumes of 5 or less due to the risk that individuals will be re-identified, as we are required to protect their identity under the General Data Protection Regulations & Data Protection Act 2018. In such circumstances Section 40(2) and Section 40(3) of the Freedom of Information Act apply. In this case, our view is that disclosure would breach the first data protection principle which states that personal data should be processed “lawfully, fairly and in a transparent manner”. It is the lawful aspect of this principle which, in our view, would be breached by disclosure, and in such circumstances, Section 40 confers an absolute exemption on disclosure.

- 2. How many patients has your Trust treated with Rituximab for MS (Multiple Sclerosis) in the past six months?**

Nil

- 3. How many patients within your Trust have a diagnosis of MS (Multiple Sclerosis)?**

175 patients in the last six months.

- 4. Of the patients with a diagnosis of Multiple Sclerosis, how many patients have a diagnosis of:**

We do not hold this level of detail.